| Project/Area Number |
10671472
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
NONOMURA Norio Osaka University Graduate School of Medicine, Assistant Professor, 医学系研究科, 講師 (30263263)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOJIMA Yasuyuki Osaka University Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (50273628)
MIKI Tsuneharu Kyoto Prefectural University of Medical School, Professor, 医学部, 教授 (10243239)
OKUYAMA Akihiko Osaka University Graduate School of Medicine, Professor, 医学系研究科, 教授 (20093388)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1998: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | renal cell carcinoma / genetic alteration / CPT-11 / interleukin 2 / interleukin 7 / apoptosis / Fas / soluble Fas / 遺伝子 / LOH解析 / VHL遺伝子 / FHIT遺伝子 / インターフェロン / LAK療法 / IL2 |
|---|
| Research Abstract |
We have already demonstrated that alteration of genomic imprinting was observed in renal cancer. However, we could not detect the relationship between abnormal epigenetic changes and biological characteristics of renal cancer. CPT-11 showed strong antitumor effect against human renal cancer heterotransplanted in nude mice. CPT-11 can be a new candidate as a therapeutic drug for renal cell carcinoma in the future. Enhancement of interleukin 2-induced lymphokine-activated killer activity by interleukin 7 has been shown against autologous human renal cell carcinoma. Clinical usefulness of this combination therapy against renal cancer has been demonstrated. Susceptibility of brain metastasis by interleukin 2 was neglected by our retrospective study. In terms of apoptosis-related genes, renal cancer cells expressed Fas and showed apoptosis by anti-Fas agonistic antibody. Moreover, this apoptosis was enhanced by interferon-_. In vivo experiments, Fas ligand-transfected mouse renal cancer cells showed more rapid growth than the control cancer cells, probably due to the evasion from T-cell attack. Soluble Fas was detected in high level in the serum from patients with renal cell carcinoma. This may be clinically useful for detecting metastasis or recurrence.
|
